Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graeme J Finlay

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Plos One|July 7, 2015
Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell LinesEuphemia Y Leung, Marjan Askarian-Amiri, Graeme J Finlay, et al.
Cancer Genetics|October 25, 2011
Centrosomal dysregulation in human metastatic melanoma cell linesGeoffrey A Charters, Clare J Stones, Andrew N Shelling, et al.
Investigational New Drugs|June 23, 2010
Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposideCatherine J Drummond, Graeme J Finlay, Laura Broome, et al.
Investigational New Drugs|August 11, 2010
In vivo and in vitro assessment of the action of SN 28049, a benzonaphthyridine derivative targeting topoisomerase II, on the murine Colon 38 carcinomaYing Yi Chen, Graeme J Finlay, James A Kirker, et al.
Bioorganic & Medicinal Chemistry|May 2, 2002
Synthesis and cytotoxic activity of N-(2-diethylamino)ethylcarboxamide and other derivatives of 10H-quindolineJunjie Chen, Leslie W Deady, Anthony J Kaye, et al.
Plos One|August 30, 2014
Relationships between signaling pathway usage and sensitivity to a pathway inhibitor: examination of trametinib responses in cultured breast cancer linesEuphemia Y Leung, Ji Eun Kim, Marjan Askarian-Amiri, et al.
Cancer Chemotherapy and Pharmacology|September 17, 2013
Tumour tissue selectivity in the uptake and retention of SN 28049, a new topoisomerase II-directed anticancer agentPradeep B Lukka, Ying Yi Chen, Graeme J Finlay, et al.
Frontiers in Oncology|September 21, 2017
Endocrine Therapy of Estrogen Receptor-Positive Breast Cancer Cells: Early Differential Effects on Stem Cell MarkersEuphemia Y Leung, Marjan E Askarian-Amiri, Debina Sarkar, et al.
Biology Direct|November 23, 2016
ZFAS1: a long noncoding RNA associated with ribosomes in breast cancer cellsHerah Hansji, Euphemia Y Leung, Bruce C Baguley, et al.
Cancer Chemotherapy and Pharmacology|May 8, 2014
Selective cellular uptake and retention of SN 28049, a new DNA-binding topoisomerase II-directed antitumor agentYing Yi Chen, Pradeep B Lukka, Wayne R Joseph, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Plos One|July 7, 2015
Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell LinesEuphemia Y Leung, Marjan Askarian-Amiri, Graeme J Finlay, et al.
Cancer Genetics|October 25, 2011
Centrosomal dysregulation in human metastatic melanoma cell linesGeoffrey A Charters, Clare J Stones, Andrew N Shelling, et al.
Investigational New Drugs|June 23, 2010
Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposideCatherine J Drummond, Graeme J Finlay, Laura Broome, et al.
Investigational New Drugs|August 11, 2010
In vivo and in vitro assessment of the action of SN 28049, a benzonaphthyridine derivative targeting topoisomerase II, on the murine Colon 38 carcinomaYing Yi Chen, Graeme J Finlay, James A Kirker, et al.
Bioorganic & Medicinal Chemistry|May 2, 2002
Synthesis and cytotoxic activity of N-(2-diethylamino)ethylcarboxamide and other derivatives of 10H-quindolineJunjie Chen, Leslie W Deady, Anthony J Kaye, et al.
Plos One|August 30, 2014
Relationships between signaling pathway usage and sensitivity to a pathway inhibitor: examination of trametinib responses in cultured breast cancer linesEuphemia Y Leung, Ji Eun Kim, Marjan Askarian-Amiri, et al.
Cancer Chemotherapy and Pharmacology|September 17, 2013
Tumour tissue selectivity in the uptake and retention of SN 28049, a new topoisomerase II-directed anticancer agentPradeep B Lukka, Ying Yi Chen, Graeme J Finlay, et al.
Frontiers in Oncology|September 21, 2017
Endocrine Therapy of Estrogen Receptor-Positive Breast Cancer Cells: Early Differential Effects on Stem Cell MarkersEuphemia Y Leung, Marjan E Askarian-Amiri, Debina Sarkar, et al.
Biology Direct|November 23, 2016
ZFAS1: a long noncoding RNA associated with ribosomes in breast cancer cellsHerah Hansji, Euphemia Y Leung, Bruce C Baguley, et al.
Cancer Chemotherapy and Pharmacology|May 8, 2014
Selective cellular uptake and retention of SN 28049, a new DNA-binding topoisomerase II-directed antitumor agentYing Yi Chen, Pradeep B Lukka, Wayne R Joseph, et al.
Pageof 3